Erik’s experience includes positions at GenVault Corporation (CEO), Exiqon A/S (CCO) and Becton Dickinson (vice president of marketing and development). In 2001, Erik led the formation and financing efforts of GeneOhm Sciences, Inc. and orchestrated the company’s acquisition by Becton Dickinson in 2006. He also served as an entrepreneur in residence (EIR) at leading life-science venture capital firm Domain Associates, LLC.

Erik was a National Institutes of Health postdoctoral fellow at Harvard University and a National Science Foundation predoctoral fellow at the California Institute of Technology, Pasadena (Caltech). He holds a PhD in chemistry from Caltech and MBAs from UC Berkeley and Columbia University.

The post Erik Holmlin, PhD appeared first on bionanogenomics.

The post Gülsen Kama appeared first on bionanogenomics.

Prior to joining Bionano Genomics, Mark led a global team at Brooks Life Science Systems in the development of sample analyzers, high-throughput screening solutions, and chemical storage and biobank systems. Prior to his time at Brooks, Mark was with Affymetrix, where he launched the array platform that is widely used today for GWAS and other genomics applications. Mark also spent time at Siemens Healthcare Diagnostics on the development of equipment for diagnostic core labs.

During his 13 years at Life Technologies (formerly Applied Biosystems) he held various levels of responsibility in the development of systems for real-time PCR, sequencing and sample preparation. Mark holds a bachelor’s degree in electrical engineering and a master’s degree in computer and systems engineering from Rensselaer Polytechnic Institute in New York.

The post Mark Oldakowski appeared first on bionanogenomics.

Previously, she was the Head of Cytogenomics at PerkinElmer Genomics, where Dr. Chaubey led the successful development and launch of several innovative products including the CNGnome test (low-pass whole genome sequencing), and a new FSHD assay utilizing Saphyr. She has also played an integral role on Vanadis team at PerkinElmer in their efforts to bring a new PCR-free NIPT technology to the market. Prior to PerkinElmer Genomics, Dr. Chaubey was the Director of the Cytogenomics Laboratory at the Greenwood Genetic Center, SC, USA. She also holds an academic appointment as the Scientific Director of the Georgia Esoteric and Molecular Laboratory, Scientific Director of the Cytogenetics Laboratory of the Augusta University Medical Center and Adjunct Assistant professor of Pathology of the medical College of Georgia at Augusta University.

Dr. Chaubey serves on the Board of Directors for the Cancer Genomics Consortium and is also the Genetics Subdivision Nominating Committee representative of the Association of Molecular Pathologists (AMP). She originally received her Doctorate degree (PhD) from Guru Nanak Dev University, Amritsar, India and completed her post-doctoral studies at Center for Cellular and Molecular Biology (CCMB), Hyderabad, India, and University of Illinois at Chicago (UIC).

The post Alka Chaubey, PhD, FACMG appeared first on bionanogenomics.

Prior to joining Bionano, where he has held different sales leadership positions covering EMEA, APAC and global regions, Stan led a sales and support team at Fluidigm, bringing the sales of microfluidic systems for high-throughput qPCR and single-cell analysis from the early stages to complete adoption on the French market. Before that, he also led sales development successes at Pyrosequencing-Biotage and then Qiagen on the emerging next-generation sequencing (NGS) market for single-nucleotide polymorphism (SNP) genotyping and methylation analysis.

Stan received his Master of Science in biology from University Pierre et Marie Curie – Paris 6 and his MBA from IAE Paris, business school of the University Pantheon-Sorbonne – Paris 1.

The post Stanislas Marin, MS, MBA appeared first on bionanogenomics.

Alex joined Bionano from Illumina, where he was Director of Clinical Segment Marketing for the Americas region and was responsible for key segment marketing strategies including oncology testing, reproductive health, genetic disease testing and infectious disease testing. Prior to his role in regional marketing, Alex was the global lead for Illumina’s Reproductive Health (RH) product team where he worked to bring advanced solutions in prenatal testing to market. Alex received a Bachelor of Science in biology and physiology from University of Minnesota and an MBA in marketing from University of California, San Diego.

The post Alex Helm, MBA appeared first on bionanogenomics.

She joined Bionano from Exact Sciences, where she most recently held the role of Vice President, U.S. Managed Care and Reimbursement. Donna has obtained coverage and reimbursement for some of the most valued diagnostics of the last several decades. She received a bachelor’s degree in biology from Queens College and a master’s degree in organizational leadership from Mercy College.

The post Donna Polizio appeared first on bionanogenomics.

Alex received training during his PhD in cancer genetics, biochemistry, and biophysics at the Roswell Park Cancer Institute. He focused his research on novel technology and received a patent as coinventor for a method for detection of protein-protein interactions.

After a post-doctoral fellowship at the Max Planck Institute in Munich, Germany, he joined Bionano Genomics as a scientist, where he has been an inventor on multiple patents and coauthored over 90 peer reviewed publications. Currently, Alex serves as vice president of clinical and scientific affairs where he leads clinical trials and the company’s scientific publication portfolio.

The post Alex Hastie, PhD appeared first on bionanogenomics.

He joined Bionano Laboratories in 2021, bringing his passion of delivering exceptional diagnostic services to both health care providers and patients. Before joining Bionano Laboratories, Justin served in leadership roles at several large diagnostic companies, including PerkinElmer and GeneDx. Justin is a certified genetic counselor who received a master’s degree from Arcadia University and a bachelor’s degree in diagnostic genetic sciences from the University of Connecticut.

The post Justin Leighton appeared first on bionanogenomics.

 Prior to joining Bionano, he was a senior research and development manager at Thermo Fisher. Patrick also led verification and validation projects across a variety of genomic and proteomic technologies at companies including Life Technologies and Applied Biosystems.

Patrick holds a bachelor’s degree in chemical engineering from University of California, Los Angeles, and a PhD in bioengineering from UC San Diego.

The post Patrick Lynch, PhD appeared first on bionanogenomics.